RT Journal Article
SR Electronic
T1 Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP S20
OP S25
DO 10.1097/IGC.0000000000000289
VO 24
IS Supp 3
A1 Aikou Okamoto
A1 Rosalind M. Glasspool
A1 Seiji Mabuchi
A1 Noriomi Matsumura
A1 Hiroyuki Nomura
A1 Hiroaki Itamochi
A1 Masashi Takano
A1 Tadao Takano
A1 Nobuyuki Susumu
A1 Daisuke Aoki
A1 Ikuo Konishi
A1 Alan Covens
A1 Jonathan Ledermann
A1 Delia Mezzazanica
A1 Christopher Steer
A1 David Millan
A1 Iain A. McNeish
A1 Jacobus Pfisterer
A1 Sokbom Kang
A1 Laurence Gladieff
A1 Jane Bryce
A1 Amit Oza
YR 2014
UL http://ijgc.bmj.com/content/24/Supp_3/S20.abstract
AB Abstract Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than high-grade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.